11.4 - Antiplatelet therapy in OAC

Left atrial appendage closure vs oral anticoagulation for atrial fibrillation: PRAGUE 17: 4 years


to report the 4-year follow-up clinical outcomes comparing left atrial appendage closure (LAAC) with non-warfarin oral anticoagulation for (DOAC) atrial fibrillation (WATCHMAN or AMULET)


prospective multicentre randomised non-inferiority trial (margin 5%)


patients with nonvalvular AF at moderate or high risk for stroke or bleeding (CHA2DS2-VASc ≥3 plus HAS-BLED ≥2)


composite of stroke or TIA, systemic embolism, clinically significant bleeding, death or periprocedural complication




LAAC remains non-inferior to DOAC during median follow-up of 3.5 years for prevention of major cardiovascular, neurological and bleeding events

Osmancik et al. J Am Coll Cardiol. 2022;79:1-14

View next trial
Drug-eluting stents in elderly patients with coronary artery disease: SENIOR

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Latest news